• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novo Nordisk

Semaglutide paired with behavioral therapy tripled weight loss in trial

February 24, 2021 By Brian Buntz

Novo Nordisk

The diabetes drug Ozempic (semaglutide) could potentially enhance weight loss in overweight and obese patients without diabetes, according to a study recently published in JAMA and The New England Journal of Medicine. In December, Novo Nordisk (NYSE:NVO) submitted a new drug application to the FDA for a 2.4-mg dose of subcutaneous semaglutide for chronic weight management. Get the full story […]

Filed Under: Diabetes Tagged With: Diabetes, Novo Nordisk, semaglutide

Lilly and Ypsomed team up on automated insulin delivery

November 19, 2020 By Brian Buntz

Eli Lilly

Eli Lilly (NYSE:LLY) and Ypsomed (SWX:YPSN) are teaming up to create an automated insulin delivery system. Lilly would commercialize the device, which would incorporate an insulin pump from Ypsomed. Burgdorf, Switzerland-based Ypsomed launched its Mylife YpsoPump in Europe in 2016. Now available in 21 countries, the pump includes a touch screen. Lilly plans on commercializing […]

Filed Under: Diabetes, Drug-Device Combinations Tagged With: Eli Lilly & Co., Novo Nordisk, Ypsomed, YpsoPump

7 medtech advances to improve diabetes treatment

January 10, 2020 By Sean Whooley

Medtech and pharmaceutical companies have made several important strides over the past year when it comes to improving diabetes treatment. Multiple treatments and technologies have cleared regulatory hurdles and are now hitting the market and making the process of living with diabetes that much more manageable. Several different styles of therapy and devices have come […]

Pages: Page 1 Page 2

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Technology Tagged With: dariohealth, FDA, Medtronic, Novo Nordisk, One Drop, optiscanbiomedical, popsdiabetescare, Senseonics, Tandem Diabetes Care, Valeritas Inc.

Insulet wins FDA nod for Omnipod with Novo Nordisk’s Fiasp insulin

October 28, 2019 By Sean Whooley

Insulet

Insulet (NSDQ:PODD) said last week that it won FDA clearance for the use of Novo Nordisk‘s (NYSE:NVO) Fiasp insulin with the Omnipod insulin management platform. Acton, Mass.-based Insulet said it completed extensive testing to ensure that Fiasp is safe and usable with the Omnipod and Omnipod Dash systems. It’s the first insulin pump in the U.S. […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA) Tagged With: FDA, Insulet, Novo Nordisk

Abbott, Medtronic ink diabetes pacts with Sanofi, Novo Nordisk

September 16, 2019 By Danielle Kirsh

abbott-sanofi-medtronic-novo-nordisk

Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) today announced separate data-sharing deals for digital diabetes management solutions. Abbott is partnering with Sanofi (NYSE:SNY) to integrate glucose sensing and insulin delivery to help people manage their diabetes. The two companies plan to develop tools to combine Abbott’s FreeStyle Libre technology with insulin dosing information for smart pens, insulin titration apps and […]

Filed Under: Diabetes, Diagnostics, Patient Monitoring Tagged With: abbott, Medtronic, Novo Nordisk, sanofi

Novo Nordisk seeks FDA nod for oral diabetes pill

March 21, 2019 By Sarah Faulkner

Novo Nordisk - updated logo

Novo Nordisk (NYSE:NVO) said this week that it submitted applications to the FDA for its oral formulation of semaglutide, a once-daily glucagon-like peptide-1 receptor agonist therapy. The company is hoping its pill will be approved as an adjunct to diet and exercise to improve blood sugar control in adults with Type 2 diabetes. Novo Nordisk also […]

Filed Under: Clinical Trials, Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: Novo Nordisk

Glooko, Novo Nordisk team up for connected insulin pens

February 25, 2019 By Sarah Faulkner

Glooko

Glooko announced this month that it’s teaming up to connect Novo Nordisk‘s (NYSE:NVO) insulin pens with the company’s diasend diabetes management solution. Novo Nordisk plans to launch its connected insulin pens, the NovoPen 6 and NovoPen Echo Plus, in early 2019. Any provider using diasend and any person using the diasend mobile app will be able […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: DexCom Inc., glooko, Insulet, Novo Nordisk

Abbott, Novo Nordisk ink deal for digital diabetes tools

February 20, 2019 By Sarah Faulkner

Abbott, Novo Nordisk partnership

Abbott (NYSE:ABT) said today that it inked a non-exclusive deal to integrate insulin dose data from Novo Nordisk‘s (NYSE:NVO) pre-filled and connected pens with its FreeStyle Libre mobile app and cloud-based system. The companies touted that integrating the products will allow healthcare professionals, caregivers and users to easily view glucose and insulin data, as well as […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, mHealth (Mobile Health), Pharmaceuticals, Wall Street Beat Tagged With: abbott, Novo Nordisk

Study: Researchers develop ingestible capsule for insulin delivery

February 11, 2019 By Sarah Faulkner

A team of researchers from MIT developed an ingestible, blueberry-sized capsule that can deliver insulin orally. In animal models, the capsule lowered blood sugar levels and performed comparably with the traditional route of insulin delivery – injections. The capsule features a small needle made of freeze-dried, compressed insulin. The needle is attached to a compressed […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: Brigham & Women's Hospital, Massachusetts Institute of Technology, National Institutes of Health, Novo Nordisk

Pharma stocks fall as Rep. Cummings launches drug pricing investigation

January 14, 2019 By Sarah Faulkner

Pills

Chairman of the House Oversight Committee Rep. Elijah Cummings (D-MD) launched an investigation today into the drug pricing practices of 12 pharmaceutical companies. A number of companies named in the investigation saw their stock prices fall, including Amgen (NSDQ:AMGN), AbbVie (NYSE:ABBV), AstraZeneca (NYSE:AZN), Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). A hearing is reportedly set for Jan. 29 and will […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: AbbVie, Amgen, AstraZeneca plc, Eli Lilly & Co., Novo Nordisk, Sanofi-Aventis

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 7
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS